MDT

100.19

-0.4%↓

147.66

-0.31%↓

VEEV

240.37

+1.66%↑

HQY

98.78

+1.46%↑

PHR.US

17.07

-0.7%↓

MDT

100.19

-0.4%↓

147.66

-0.31%↓

VEEV

240.37

+1.66%↑

HQY

98.78

+1.46%↑

PHR.US

17.07

-0.7%↓

MDT

100.19

-0.4%↓

147.66

-0.31%↓

VEEV

240.37

+1.66%↑

HQY

98.78

+1.46%↑

PHR.US

17.07

-0.7%↓

MDT

100.19

-0.4%↓

147.66

-0.31%↓

VEEV

240.37

+1.66%↑

HQY

98.78

+1.46%↑

PHR.US

17.07

-0.7%↓

MDT

100.19

-0.4%↓

147.66

-0.31%↓

VEEV

240.37

+1.66%↑

HQY

98.78

+1.46%↑

PHR.US

17.07

-0.7%↓

Home・Aktien・Vivani Medical

Vivani Medical

Open

1.26 -1.56

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

1.24

Max

1.3

Schlüsselkennzahlen
By Trading Economics
Angestellte	37

Empfehlungen
By TipRanks
Empfehlungen	Buy
12-Monats-Prognose	+210.08% upside

Dividenden
By Dow Jones
Nächstes Ergebnis	30. März 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	-21M 83M
Vorheriger Eröffnungskurs	2.82
Vorheriger Schlusskurs	1.26

Vivani Medical Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

7. Jan. 2026, 23:11 UTC

Ergebnisse

Samsung Electronics Expects Record Fourth-Quarter Profit Beat

7. Jan. 2026, 22:55 UTC

Wichtige Markttreiber

Defense Stocks Rebound After Trump Says He Wants $1.5 Trillion Military Budget in 2027

7. Jan. 2026, 21:39 UTC

Wichtige Markttreiber

Raytheon Down Following Trump Post Criticizing Company

7. Jan. 2026, 20:13 UTC

Wichtige Markttreiber

AbbVie, Revolution Medicines Stocks Gain on Report of Possible Acquisition

7. Jan. 2026, 20:03 UTC

Wichtige Markttreiber

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Executive Pay

7. Jan. 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

7. Jan. 2026, 23:46 UTC

Market Talk

Nikkei May Decline as China-Japan Tensions Linger -- Market Talk

7. Jan. 2026, 23:42 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 5th Update

7. Jan. 2026, 23:34 UTC

Market Talk

Gold Edges Higher Amid Lingering Geopolitical Risks -- Market Talk

7. Jan. 2026, 23:29 UTC

Akquisitionen, Fusionen, Übernahmen

Constellation Closes Deal for Calpine, Creating Biggest Electricity Generator -- Barrons.com

7. Jan. 2026, 22:48 UTC

Market Talk

Infratil's Discount to Net Asset Value Too Good to Ignore -- Market Talk

7. Jan. 2026, 22:46 UTC

Ergebnisse

Samsung Electronics Estimates 2025 Rev KRW332.770T Vs KRW300.870T >005930.SE

7. Jan. 2026, 22:45 UTC

Ergebnisse

Samsung Electronics Estimates 2025 Oper Pft KRW43.530T Vs KRW32.730T >005930.SE

7. Jan. 2026, 22:43 UTC

Akquisitionen, Fusionen, Übernahmen

Revolution Medicines Draws Takeover Interest -- 2nd Update

7. Jan. 2026, 22:42 UTC

Ergebnisse

Samsung Electronics 4Q Oper Pft Estimate Beat FactSet-Compiled Consensus Forecast

7. Jan. 2026, 22:41 UTC

Ergebnisse

Samsung Electronics Sees 4Q Oper Pft KRW20.000T Vs KRW6.490T >005930.SE

7. Jan. 2026, 22:41 UTC

Ergebnisse

Samsung Electronics Sees 4Q Rev KRW93.000T Vs KRW75.790T >005930.SE

7. Jan. 2026, 22:40 UTC

Wichtige Markttreiber

Defense Stocks Rebound After Trump Says He Wants $1.5T Military Budget in 2027

7. Jan. 2026, 22:31 UTC

Market Talk

Macro Tailwinds Strengthen for Chalice Mining -- Market Talk

7. Jan. 2026, 22:22 UTC

Market Talk

Northern Star's Run of Disruptions Increasingly a Concern -- Market Talk

7. Jan. 2026, 22:01 UTC

Market Talk

Valuations of New Zealand Property Stocks Supportive -- Market Talk

7. Jan. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

7. Jan. 2026, 21:46 UTC

Market Talk

Northern Star's Revised Guidance Looks Achievable -- Market Talk

7. Jan. 2026, 21:22 UTC

Akquisitionen, Fusionen, Übernahmen

Eli Lilly to Buy Ventyx Biosciences for $14 a Share >LLY VTYX

7. Jan. 2026, 21:18 UTC

Akquisitionen, Fusionen, Übernahmen

Lilly To Acquire Ventyx Biosciences To Advance Oral Therapies Targeting Inflammatory-mediated Diseases >LLY VTYX

7. Jan. 2026, 21:05 UTC

Akquisitionen, Fusionen, Übernahmen

Warner Discovery Rejects Paramount's Amended Hostile Bid -- 4th Update

7. Jan. 2026, 20:29 UTC

Akquisitionen, Fusionen, Übernahmen

AbbVie Near Deal for Revolution Medicines -- Update

7. Jan. 2026, 20:27 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

7. Jan. 2026, 19:58 UTC

Market Talk

Oil Falls As U.S. to Receive Sanctioned Venezuelan Crude -- Market Talk

7. Jan. 2026, 19:48 UTC

Wichtige Markttreiber

Defense Contractor Shares Fall on Trump's Push to Ban Industry Dividends, Buybacks, Limit Exec Pay

Peer-Vergleich

Kursveränderung

Vivani Medical Prognose

Kursziel

By TipRanks

210.08% Vorteil

12-Monats-Prognose

Durchschnitt 4 USD 210.08%

Hoch 4 USD

Tief 4 USD

Basierend auf 2 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Vivani Medical – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

2 ratings

Buy

Halten

Sell

Basierend auf 2 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Vivani Medical – Dist abgegeben haben.

Finanzen

Über Vivani Medical

Vivani Medical, Inc., a preclinical stage biopharmaceutical company, engages in the development of miniaturized and subdermal implants that treat chronic diseases. The company uses its NanoPortal implant technology to develop and potentially commercialize drug implant candidates in the treatment of chronic disease, medication non-adherence. Its pipeline includes NPM-115, a high-dose exenatide implant candidate is in preclinical stage development for the treatment of chronic weight management in patients with obesity or overweight; NPM-119, an exenatide implant candidate is in preclinical stage development for the treatment of patients with type 2 diabetes; NPM-139, a miniature, subdermal GLP-1 implant in development for chronic weight management; and OKV-119, an exenatide implant is under development for metabolic diseases in cats including for the treatment of obesity and diabetes. The company is headquartered in Alameda, California.